YCT-529 tablet for non-hormonal male contraception in development
Official title: Tablet development and relative bioavailability study in men for ongoing clinical development of YCT-529 as an oral non-hormonal male contraceptive
Funded at Yourchoice Therapeutics, INC. · NIH-11403572 · Data updated 2026-11-12
A new oral male birth-control pill (YCT-529) is being studied to safely and reversibly reduce sperm production in men.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yourchoice Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Berkeley, UNITED STATES) |
| Project start | September 20, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $994,056 |
| NIH project number | 1R44HD120117-01A1 |
| Project ID | NIH-11403572 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adult men interested in exploring a non-hormonal, reversible contraceptive option could participate in future trials when available.
✕Less likely to help
Men who do not wish to pursue contraception or who experience adverse effects may not benefit.
What this research studies
This grant supports the ongoing development of YCT-529, a non-hormonal pill that temporarily lowers sperm production by targeting retinoic acid signaling. The project includes a tablet formulation and a study of how well the drug is absorbed when taken as a capsule, to guide dose decisions for later trials. Men who are participating are receiving rising doses over weeks to understand safety, tolerability, and the potential to suppress sperm while remaining reversible. The research builds on early human trials showing tolerability and seeks to advance toward larger studies with the goal of offering a new option for male contraception.
Why it matters
Potential benefit: If successful, this work could lead to a reversible, non-hormonal birth-control option for men.
How similar studies have gone: Prior Phase 1a results showed tolerability across a range of single doses, with ongoing multiple-dose testing.
Where this research is happening
-
Yourchoice Therapeutics, INC.
Berkeley, United States Active
Researchers
- Principal investigator: Mannowetz, Nadja — Yourchoice Therapeutics, INC.
- Study coordinator: Mannowetz, Nadja
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.